Alcon, Novartis deal

Novartis completed its previously announced deal to acquire the remaining portion of Alcon it does not already own in a cash and stock deal. Alcon shareholders received $168 per share, comprising up to 2.9 Novartis shares and $8.20 in cash, valued at $9.5 billion. Novartis said it had purchased 16.1 million Alcon shares on the open market since last December. Alcon had 2010 sales of $7.2 billion. ...